Bayer's US chief warns that Americans no longer want to subsidize global drug research: "We're at the beginning of a new order".
Sebastian Guth has significantly expanded the pharmaceutical division of the traditional German group in the USA since 2018. Despite Trump's pressure on the industry, he has big growth plans for the country.
We haven't written up this one. NZZ Wirtschaft has the full story — the link below goes straight to it.